Combined use of <scp>CLP290</scp> and bumetanide alleviates neuropathic pain and its mechanism after spinal cord injury in rats
Combined application of CLP290 and bumetanide effectively increases the ratio of KCC2/NKCC1, restores RDD levels, enhances GABA<sub>A</sub> receptor-mediated inhibitory function in the spinal cord, and relieves neuropathic pain in SCI; Bumetanide significantly improves neuropathic pain in the long term, whereas CLP290 demonstrates a notable short-term effect.
Authors
- Zuliyaer Talifu
- Xin Ping Xu (ORCID: https://orcid.org/0000-0002-6324-5211)
- Han Ke
- Feng Gao (ORCID: https://orcid.org/0000-0002-4902-7429)
- Chunjia Zhang
- Jianjun Li (ORCID: https://orcid.org/0000-0002-8441-7537)
- Xiaoxin Wang (ORCID: https://orcid.org/0000-0003-1282-8481)
- Yan Yu (ORCID: https://orcid.org/0000-0003-0940-5920)
- Degang Yang (ORCID: https://orcid.org/0000-0002-2212-6793)
- Liangjie Du
- Yunzhu Pan (ORCID: https://orcid.org/0000-0001-5505-5031)
Institutions
- Capital Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- China Rehabilitation Research Center (CN)
- Chinese Institute for Brain Research (CN)
Publication Details
- Journal
- CNS Neuroscience & Therapeutics
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1111/cns.70045
- Citations
- 5
- Primary Topic
- Pain Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.63